PETIGNOT, Sandrine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
CASTERMANS, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Unité de laboratoire - endocrino - métabolique
Korpershoek, Esther
Scagnol, Irène ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
BECKERS, Pablo ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Pool assistant - biologie clinique
Dideberg, Vinciane ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Rohmer, Vincent ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Pancreatic neuroendocrine neoplasm associated with a familial MAX deletion
Dasari A. Shen C. Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol: 2017; 3 1335 1342
Thakker R. V. Newey P. J. Walls G. V. et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab: 2012; 97 2990 3011
Di Domenico A. Wiedmer T. Marinoni I. et al. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer: 2017; 24 R315 R334
Hammel P. R. Vilgrain V. Terris B. et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d′Etude de la Maladie de von Hippel-Lindau. Gastroenterology: 2000; 119 1087 1095
Agaimy A. Vassos N. Croner R. S. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): Clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol: 2012; 5 852 862
Barrera A. S. Serra Pla S. Blázquez Maña C. M. et al. Pancreatic non-functioning neuroendocrine tumor: A new entity genetically related to Lynch syndrome. J Gastrointest Oncol: 2017; 8 E73 E79
Neychev V. Sadowski S. M. Zhu J. et al. Neuroendocrine tumor of the pancreas as a manifestation of cowden syndrome: A case report. J Clin Endocrinol Metab: 2016; 101 353 358
Mortaji P. Morris K. T. Samedi V. et al. Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: Case report and review of the literature. Fam Cancer: 2018; 17 275 280
Alrezk R. Hannah-Shmouni F. Stratakis C. A. MEN4 and CDKN1B mutations: The latest of the MEN syndromes. Endocr Relat Cancer: 2017; 24 T195 T208
Comino-Méndez I. Gracia-Aznárez F. J. Schiavi F. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet: 2011; 43 663 667
Burnichon N. Cascon A. Schiavi F. et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res: 2012; 18 2828 2837
Korpershoek E. Koffy D. Eussen B. H. et al. Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis. J Clin Endocrinol Metab: 2016; 101 453 460
Casey R. T. Warren A. Y. Martin J. E. et al. Clinical and molecular features of renal and pheochromocytoma/paraganglioma tumor association syndrome (RAPTAS): Case series and literature review. J Clin Endocrinol Metab: 2017; 102 4013 4022
Romero O. A. Torres-Diz M. Pros E. et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov: 2014; 4 292 303
Pantaleo M. A. Urbini M. Indio V. et al. Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res: 2017; 15 553 562
Roszko K. L. Blouch E. Blake M. et al. Case report of a prolactinoma in a patient with a novel MAX mutation and bilateral pheochromocytomas. J Endocr Soc: 2017; 1 1401 1407
Daly A. F. Castermans E. Oudijk L. et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr Relat Cancer: 2018; 25 L37 L42
Falconi M. Eriksson B. Kaltsas G. et al. ENETS Consensus Guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology: 2016; 103 153 171
Bausch B. Schiavi F. Ni Y. et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncol: 2017; 3 1204 1212
Schaefer I. M. Wang Y. Liang C. W. et al. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun: 2017; 8 14674
Mafficini A. Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev: 2019; 40 506 536
Scarpa A. Chang D. K. Nones K. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature: 2017; 543 65 71
Jiao Y. Shi C. Edil B. H. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science: 2011; 331 1199 1203
Albattal S. Alswailem M. Moria Y. et al. Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma. Oncotarget: 2019; 10 5919 5931
